Approval · Notice of Compliance 15421 · 2014
MINT-ZOLMITRIPTAN: Notice of Compliance 15421
Issued March 18, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15421
- Date
- March 18, 2014
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
- Canadian reference product
- ZOMIG (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-ZOLMITRIPTAN | 02419521 | Marketed |
Medicinal ingredients
- ZOLMITRIPTAN 2.5 MG per TAB